OZC-003

OZC-003 is a preclinical-stage therapeutic candidate developed by ONCOZEN for the treatment of resistant non-small cell lung cancer (NSCLC). It utilizes a novel modality known as Chaperone-Mediated Protein Degradation (CMPD) to target and degrade the c-MET protein (hepatocyte growth factor receptor). Unlike traditional tyrosine kinase inhibitors that merely block signaling, OZC-003 is designed to eliminate the c-MET protein entirely by leveraging the cell's internal chaperone-mediated degradation machinery. This approach is intended to overcome resistance mechanisms associated with c-MET alterations, such as amplification or mutations, which frequently occur in advanced lung cancers.